Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 1/20 | 0.54 |
| ▸ | ACACB | O00763 | 1/20 | 0.52 |
| ▸ | ACACA | Q13085 | 1/20 | 0.52 |
| ▸ | ODC1 | P11926 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | BLM | P54132 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.45 |
| ▸ | PPARA | Q07869 | 4/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.40 |
| ▸ | GABRP | O00591 | 1/20 | 0.40 |
| ▸ | GABRD | O14764 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3506267 | 0.98 | ACLY (0.52) | ACLYACACBACACAODC1LMNA | |
| SCHEMBL9718212 | 0.93 | ACLY (0.57) | ACLYACACBACACAODC1LMNA | |
| SCHEMBL10870768 | 0.91 | ACLY (0.61) | ACLYACACBACACAODC1LMNA | |
| SCHEMBL10869894 | 0.91 | ACLY (0.61) | ACLYACACBACACAODC1LMNA | |
| SCHEMBL9350070 | 0.91 | ACLY (0.61) | ACLYACACBACACAODC1LMNA | |
| SCHEMBL28439734 | 0.91 | ACLY (0.61) | ACLYACACBACACAODC1LMNA | |
| SCHEMBL10870280 | 0.91 | ACLY (0.61) | ACLYACACBACACAODC1LMNA | |
| SCHEMBL10548846 | 0.88 | ACLY (0.52) | ACLYACACBACACAODC1LMNA | |
| SCHEMBL205335 | 0.84 | — | — | |
| SCHEMBL2784372 | 0.84 | ACLY (0.62) | ACLYACACBACACASMN1; SMN2PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368150-A1 | BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2024-11-07 | — | — | US | disclosed |
| EP-4291558-A1 | BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2023-12-20 | — | — | EP | disclosed |
| CN-116964048-A | Bicyclic tetrahydroazepine derivatives for the treatment of cancer | 豪夫迈·罗氏有限公司 | 2023-10-27 | — | — | CN | disclosed |
| CN-113474390-B | Polyurethane for cosmetic and process for producing polyurethane for cosmetic | 株式会社ADEKA | 2023-10-17 | — | — | CN | disclosed |
| CN-111808084-A | Novel lipids and compositions for delivery of therapeutic agents | 阿布特斯生物制药公司 | 2020-10-23 | — | — | CN | disclosed |
| CN-101693736-B | Novel peptides | 寒川贤治 | 2020-09-11 | — | — | CN | disclosed |
| CN-105709229-B | Novel lipids and compositions for delivery of therapeutic agents | 阿布特斯生物制药公司 | 2020-07-28 | — | — | CN | disclosed |
| US-9938332-B2 | Modified ghrelin peptides | Kanagawa, Kenji (JP) | 2018-04-10 | — | — | US | disclosed |
| US-9573986-B2 | Modified ghrelin peptides | KENJI KANGAWA (JP) | 2017-02-21 | — | — | US | disclosed |
| EP-2834220-B1 | 4-HYDROXY-ISOQUINOLINE COMPOUNDS AS HIF HYDROXYLASE INHIBITORS | FIBROGEN INC (US) | 2016-11-09 | — | — | EP | disclosed |
| EP-2119785-A1 | Novel peptides | Kangawa, Kenji (JP) | 2009-11-18 | — | — | EP | disclosed |
| US-20090170763-A1 | Modified gherlin peptides | KANGAWA KENJI | 2009-07-02 | — | — | US | disclosed |
| US-7385026-B1 | Modified ghrelin polypeptides | Kangawa, Kenji (JP) | 2008-06-10 | — | — | US | disclosed |
| WO-2008034122-A2 | HINDERED ESTER-BASED BIODEGRADABLE LINKERS FOR OLIGONUCLEOTIDE DELIVERY | ENZON PHARMACEUTICALS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| EP-1197496-B1 | NOVEL PEPTIDES | KANGAWA KENJI (JP) | 2007-07-11 | — | — | EP | disclosed |
| EP-1795598-A1 | Novel peptides | Kangawa, Kenji (JP) | 2007-06-13 | — | — | EP | disclosed |
| CN-1458842-A | Cell activator | SHISEIDO CO LTD (JP) | 2003-11-26 | — | — | CN | disclosed |
| EP-1197496-A1 | NOVEL PEPTIDES | Kangawa, Kenji (JP) | 2002-04-17 | — | — | EP | disclosed |
| EP-0774247-A2 | Hair care products | Ajinomoto Co., Inc. (JP) | 1997-05-21 | — | — | EP | disclosed |
| EP-0186083-A2 | N-(2-Hyxdroxyalkyl)-amino acids and their derivatives, process for their preparation and pharmaceutical compositions containing them | ASTA Pharma AG (DE) | 1986-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170763-A1 | Modified gherlin peptides | GHSR, GHRHR, GHITM | ACLY 4381/4885ACACB 4530/4885ACACA 4491/4885 |
| US-20240368150-A1 | BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER | BICRA, BRD4, CNR1 | ACLY 1040/4885ACACB 3004/4885ACACA 2645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.